[{"id":"08d3cf7e-53db-4d97-bd5c-e37278f8ab16","acronym":"","url":"https://clinicaltrials.gov/study/NCT04787263","created_at":"2021-03-08T12:53:53.051Z","updated_at":"2024-07-02T16:36:32.763Z","phase":"Phase 1/2","brief_title":"CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML","source_id_and_acronym":"NCT04787263","lead_sponsor":"Bambino Gesù Hospital and Research Institute","biomarkers":" TP53 • CD19 • TCF3 • PBX1","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement • CD19 expression","tags":["TP53 • CD19 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD19-CAR_Lenti T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/04/2021","start_date":" 03/04/2021","primary_txt":" Primary completion: 03/03/2025","primary_completion_date":" 03/03/2025","study_txt":" Completion: 03/03/2038","study_completion_date":" 03/03/2038","last_update_posted":"2021-03-26"}]